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Abstract
Background: Phosphoinositide 3-kinase (PI3K)/Akt pathway is linked to the development of asthma. Anti-malarial drug
artesunate is a semi-synthetic derivative of artemisinin, the principal active component of a medicinal plant Artemisia annua,
and has been shown to inhibit PI3K/Akt activity. We hypothesized that artesunate may attenuate allergic asthma via
inhibition of the PI3K/Akt signaling pathway.
Methodology/Principal Findings: Female BALB/c mice sensitized and challenged with ovalbumin (OVA) developed airway
inflammation. Bronchoalveolar lavage fluid was assessed for total and differential cell counts, and cytokine and chemokine
levels. Lung tissues were examined for cell infiltration and mucus hypersecretion, and the expression of inflammatory
biomarkers. Airway hyperresponsiveness was monitored by direct airway resistance analysis. Artesunate dose-dependently
inhibited OVA-induced increases in total and eosinophil counts, IL-4, IL-5, IL-13 and eotaxin levels in bronchoalveolar lavage
fluid. It attenuated OVA-induced lung tissue eosinophilia and airway mucus production, mRNA expression of E-selectin, IL-
17, IL-33 and Muc5ac in lung tissues, and airway hyperresponsiveness to methacholine. In normal human bronchial
epithelial cells, artesunate blocked epidermal growth factor-induced phosphorylation of Akt and its downstream substrates
tuberin, p70S6 kinase and 4E-binding protein 1, and transactivation of NF-kB. Similarly, artesunate blocked the
phosphorylation of Akt and its downstream substrates in lung tissues from OVA-challenged mice. Anti-inflammatory effect
of artesunate was further confirmed in a house dust mite mouse asthma model.
Conclusion/Significance: Artesunate ameliorates experimental allergic airway inflammation probably via negative
regulation of PI3K/Akt pathway and the downstream NF-kB activity. These findings provide a novel therapeutic value for
artesunate in the treatment of allergic asthma.
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Introduction
Allergic asthma is a chronic airway disorder characterized by
airway inflammation, mucus hypersecretion, and airway hyperre-
sponsiveness (AHR) [1]. Cumulative evidence revealed that these
inflammatory responses are mediated by T-helper type 2 (Th2)
cells together with mast cells, B cells and eosinophils, as well as a
number of inflammatory cytokines and chemokines [1,2]. IL-4 is
imperative for B cell isotype switching for the synthesis of
immunoglobulin (Ig)E. Allergen-induced crosslinking of IgE-
bound high affinity IgE receptors (FceRI) on the surface of mast
cells leads to degranulation and activation of mast cells, and the
release of inflammatory mediators like histamine, leukotrienes and
cytokines, and immediate bronchoconstriction [3,4]. IL-5 is vital
for the growth, differentiation, recruitment, and survival of
eosinophils which contribute to inflammation and even airway
remodeling in asthma [5]. IL-13 plays a pivotal role in the effector
phase of Th2 responses such as eosinophilic inflammation, mucus
hypersecretion, AHR and airway remodeling [6]. In addition,
chemokines such as RANTES (regulated on activation, normal T
cells expressed and secreted) and eotaxin are crucial to the delivery
of eosinophils to the airways [7]. Airway eosinophilia, together
with Th2 cytokines IL-4, IL-5 and IL-13, may ultimately
contribute to AHR in asthma [8].
Artesunateis a semi-synthetic derivative of artemisinin, a
sesquiterpenetrioxane lactone isolated from the herb Artemisia annua.
This medicinal plant has been used as a remedy for fevers and chills
for centuries in China [9]. Artemisinin derivatives including
artesunate are anti-malarial drugs effective for both uncomplicated
and severe malaria [9,10]. Besides, they have been shown to possess
anti-cancer [11,12], anti-viral [13], and anti-inflammatory
[14,15,16,17] activities. Artesunate has been reported to block the
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rheumatoid arthritis fibroblast-like synoviocytes [14]. In addition,
artesunate inhibits lipopolysaccharide-induced production of TNF-
a, IL-6 and nitric oxide (NO), and expression of toll-like receptor 4
(TLR4)andTLR9 from macrophages[15,16].Theexactmolecular
mechanism that mediates these anti-inflammatory effects by
artesunate has not been unequivocally determined. There are some
evidence pointing to the inhibition of nuclear factor NF-kB
transcriptional activity by artesunate and other artemisinin
derivatives [15,16,17]. More recently, artesunate has been found
to possess strong inhibitory activity against the phosphoinositide 3-
kinase (PI3K)/Akt signaling pathway [12,13,14].
As PI3K/Akt signaling pathway plays a critical role in the
activation and immune responses of eosinophils, T and B
lymphocytes, and mast cells [18,19,20], and genetic ablation of
PI3Kd or PI3Kc isoform in mice has been shown to dampen Th2
immune responses, eosinophilic lung infiltration, and airway
hyperresponsiveness and remodeling [21,22,23], we investigated
the effects of artesunate on various aspects of ovalbumin (OVA)-
induced Th2-mediated allergic airway inflammation in an in vivo
mouse asthma model and explored the anti-inflammatory
mechanism of action of artesunate. We also verified the anti-
inflammatory effect of artesunate in a house dust mite mouse
asthma model. Our results clearly indicate that artesunate
attenuates allergic airway inflammation and it is likely mediated
through inhibition of the PI3K/Akt signaling pathway.
Results
Artesunate suppresses OVA-induced inflammatory cell
recruitment and mucus production
Bronchoalveolar lavage (BAL) fluid was collected 24 hours after
the last OVA or saline aerosol challenge, and total and differential
cell counts were performed. OVA inhalation markedly increased
total cell and eosinophil counts, and slightly yet significantly
(p,0.05) increased macrophage, lymphocyte and neutrophil
counts, as compared with saline aerosol control. Artesunate
(3, 10 and 30 mg/kg) drastically decreased the total cell and
eosinophil counts in BAL fluid in a dose-dependent manner as
compared with the DMSO vehicle control (Figure 1A). We have
conducted flow cytometric analysis of peripheral blood leukocytes
obtained from saline-challenged, OVA-challenged, vehicle con-
trol, and artesunate-treated mice. Similar percentages of CD3+,
CD4+, CD8+ T cells, B cells (B220), NK cells (NK 1.1),
neutrophils and monocytes were observed in all mice (data not
shown). Hence, artesunate-induced reduction of eosinophil and
lymphocyte pulmonary recruitment is unlikely due to any potential
nonspecific cytotoxic effects of the drug.
Lung tissue was also collected 24 hours after the last OVA or
saline aerosol challenge. OVA aerosol challenge induced marked
infiltration of inflammatory cells into the peribronchiolar and
perivascular connective tissues as compared with saline aerosol
challenge. Artesunate (30 mg/kg) markedly diminished the
eosinophil-rich leukocyte infiltration as compared with DMSO
control (Figure 1B and 1D). On the other hand, OVA-
challenged mice, but not saline-challenged mice, developed
marked goblet cell hyperplasia and mucus hypersecretion in the
bronchi. OVA-induced mucus hypersecretion was significantly
halted by artesunate (30 mg/kg) (Figure 1C and 1E).
Artesunate reduces OVA-induced BAL fluid Th2 cytokine
levels
OVA inhalation in sensitized mice caused a notable increase in
IL-4, IL-5, IL-13 and eotaxin levels in BAL fluid as compared with
saline aerosol control (Figure 2). In contrast, BAL fluid level of
IFN-c and IL-12, two Th1 cytokines, dropped slightly in OVA-
challenged mice. Artesunate drastically reduced IL-13 and
eoxtain, and to a lesser extent, IL-4 and IL-5 levels in BAL fluid
in a dose-dependent manner as compared with DMSO control
(Figure 2). Noticeably, artesunate at 10 and 30 mg/kg could up-
regulated IFN-c and IL-12 levels in BAL fluid levels similar to
those in saline control mice. This finding implies that artesunate is
able to modify the Th2-predominant immune activity in our
OVA-induced mouse asthma model. Alternatively, the increase in
IL-12 BAL fluid level in artesunate-treated mice may be due to
enhanced IL-12 production by dendritic cells upon inhibition of
PI3K [24]. The exact mechanism that mediates up-regulation of
IFN-c and IL-12 BAL fluid levels remains to be determined.
Artesunate suppresses OVA-specific lymphocyte
responses in vitro
To assess whether artesunate treatment could suppress lympho-
cyte cytokine production, we examined OVA-specific immune
responsesin thoracic lymph node cultures.The in vitro OVA-specific
production of IL-4, IL-5 and IL-13 was markedly higher in
lymphocytes isolated from OVA-challenged mice than those from
saline-challenged mice (Figure 3). Artesunate (30 mg/kg) pretreat-
ment significantly (p,0.05) lowered the levels of IL-4, IL-5 and IL-
13. In contrast, in vitro OVA-specific IFN-c production was found to
be elevated in mice treated with artesunate (30 mg/kg). The
observed immune modulation by artesunate in vitro was OVA-
specific because ConA-induced production of IL-4, IL-5, IL-13 and
IFN-c in parallel cultures was not affected (data not shown).
Artesunate reduces OVA-induced airway
hyperresponsiveness in mice
To investigate the effect of artesunate on airway hyperrespon-
siveness (AHR) in response to increasing concentrations of
methacholine, we measured both RI and Cdyn in mechanically
ventilated mice. Rl is defined as the pressure driving respiration
divided by flow. Cdyn refers to the distensibility of the lung and is
defined as the change in volume of the lung produced by a change
in pressure across the lung. OVA-challenged mice developed
AHR which is typically reflected by high RI and low Cdyn
(Figure 4). Artesunate (30 mg/kg) dramatically reduced RI and
restored Cdyn in OVA-challenged mice in response to metha-
choline aerosol, suggesting that immune-mediated airway pathol-
ogy in vivo was modified.
Artesunate inhibits OVA-induced inflammatory gene
expression and PI3K/Akt activation in allergic airway
inflammation
OVA aerosol challenge markedly up-regulated lung mRNA level
of Muc5ac, which is essential for mucus hypersecretion [25];
inducible nitric oxide synthase (iNOS), the enzyme responsible for
nitric oxide (NO) production in allergic airway inflammation [26];
thymic stromal lymphopoietin (TSLP), a cytokine key to the
initiation of Th2 immune response [27]; IL-17 and IL-33, two
effector cytokines that have recently been shown essential for airway
inflammation and remodeling [28,29]; of chitinase family members
including acidic mammalian chitinase (AMCase), Ym2 and YKL-
40, which have recently been shown to play critical roles in airway
inflammation and remodeling [30,31,32]; and of adhesion mole-
cules such as ICAM-1, VCAM-1 and E-selectin, which are pivotal
for pulmonary recruitment of inflammatory cells like eosinophils
and lymphoctyes [7,33]. Pretreatment with artesunate (30 mg/kg)
demonstrated strong suppression of Muc5ac, iNOS, TSLP, IL-17,
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selectin, in the allergic airways (Figure 5A).
To verify that the anti-inflammatory mechanism of action by
artesunate in OVA-challenged mice was mediated through the
inhibition of the PI3K/Akt signaling pathway, we examined the
phosphorylation cascade of Akt, tuberin, p70 ribosomal S6 kinase
(p70S6K) and eukaryotic initiation factor 4E-binding protein 1
(4E-BP1) in lung tissues obtained 24 hours after the last OVA or
saline aerosol challenge. OVA challenge markedly raised the
phosphorylation state of Akt(ser
473), tuberin(thr
1462),
p70S6K(thr
389) and 4E-BP1(ser
65) as compared with saline aerosol
control (Figure 5B). Artesunate (30 mg/kg) markedly reduced the
phsophorylation of Akt, tuberin, p70S6K and 4E-BP1 to the basal
levels. Besides, PI3K/Akt pathway activation has been shown to
promote NF-kB DNA binding activity [34]. Artesunate signifi-
cantly suppressed OVA-induced NF-kB transactivation in lung
tissues to basal level (Figure 5C). Our findings suggest that
artesunate may exert its anti-inflammatory actions via inhibition of
PI3K/Akt pathway.
Artesunate inhibits EGF-induced PI3K/Akt activation in
primary human bronchial epithelial cells
To further explore anti-inflammatory mechanisms of action of
artesunate in a relevant human airway cell type, we studied the
effects of artesunate on epidermal growth factor (EGF)-induced
activation of PI3K/Akt signaling pathway and cytokine mRNA
Figure 1. Effects of artesunate on OVA-induced inflammatory cell recruitment and mucus hypersecretion. (A) Inflammatory cell counts
in BAL fluid obtained from sensitized mice 24 hours after the last saline aerosol (n=7 mice) or OVA aerosol (n=9 mice) challenge. Artesunate dose-
dependently reduced OVA-induced inflammatory cell counts in BAL fluid from sensitized mice 24 hours after the last OVA aerosol challenge (DMSO,
n=9; 3 mg/kg, n=7; 10 mg/kg, n=9; and 30 mg/kg, n=10). Differential cell counts were performed on a minimum of 500 cells to identify eosinophil
(Eos), macrophage (Mac), neutrophil (Neu), and lymphocyte (Lym). Histological sections of lung tissue eosinophilia (B, magnification6200) and mucus
secretion (C, magnification6200) 24 hours after the last challenge of saline aerosol, OVA aerosol, OVA aerosol plus DMSO, or OVA aerosol plus 30 mg/
kg artesunate were evaluated. Quantitative analyses of inflammatory cell infiltration (D) and mucus production (E) in lung sections were performed as
previously described [56]. Scoring of inflammatory cells and goblet cells was performed in at least 3 different fields for each lung section. Mean scores
were obtained from 4 animals. *Significant difference from DMSO control, p,0.05.
doi:10.1371/journal.pone.0020932.g001
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a critical role in asthma [35,36] and is a potent stimulator of
human airway epithelial cells [37]. EGF induced a rapid
phosphorylation of Akt, tuberin, p70S6K and 4E-BP1
(Figure 6A). This was accompanied with the up-regulation of
NF-kB DNA binding activity (Figure 6B). Artesunate markedly
inhibited the EGF-induced phosphorylation of Akt, tuberin,
p70S6K and 4E-BP1, and NF-kB transactivation. Furthermore,
artesunate noticeably blocked EGF-induced up-regulation of IL-6,
IL-8, monocyte chemoattractant protein-1 (MCP-1) and
RANTES mRNA expression in human bronchial epithelial cells
(Figure 6C). MTT assay was conducted to examine potential
cytotoxicity of artesunate on normal human bronchial epithelial
cells. No cytotoxicity on bronchial epithelial cells was observed
with artesunate drug concentrations (0.1–100 mM) used in the in
vitro experiments (data not shown).
Artesunate suppresses airway inflammation in a house
dust mite extract-induced asthma model
To validate the anti-inflammatory effects of artesunate in airway
inflammation more comparable to human situation, we have
developed a house dust mite mouse asthma model as described
Figure 2. Effects of artesunate on OVA-induced BAL fluid cytokine and chemokine levels. BAL fluids were collected 24 hours after the last
OVA aerosol challenge. Levels of IL-4, IL-5, IL-12, IL-13, eotaxin and IFN-c were analyzed using ELISA (n=6–9 mice). Lower limits of detection were as
follows: IL-4 and IL-5 at 4 pg/ml; IL-12, IL-13 and IFN-c at 15.6 pg/ml; and eotaxin at 2 pg/ml. Values shown are the mean 6 SEM. *Significant
difference from DMSO control, p,0.05.
doi:10.1371/journal.pone.0020932.g002
Figure 3. Effects of artesunate on OVA-specific lymphocyte response in vitro. Thoracic lymph nodes cells (n=4 mice) were harvested from
mice 24 hours after the last OVA or saline aerosol challenge, and cultured for 72 hours with medium alone or OVA (200 mg/ml). The levels of IL-4, IL-5,
IL-13 and IFN-c in culture supernatant were determined using ELISA. Values shown are the mean 6 SEM of triplicate cultures of pooled lymph node
cell suspensions. *Significant difference from DMSO control, p,0.05.
doi:10.1371/journal.pone.0020932.g003
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extract (100 mg per mouse) on day 0, day 7 and day 14 resulted a
notable increase in BAL fluid total cell and eosinophil counts, as
compare with saline control. Pre-treatment with artesunate
(30 mg/kg) significantly (p,0.05) suppressed the total and
eosinophil counts in BAL fluid as compared with the DMSO
vehicle control (Figure 7).
Discussion
PI3K is a family of lipid kinases comprising of 8 isoforms, of
which p110d and p110c PI3Ks are enriched in leukocytes and
have been shown to play a critical role in the activation,
proliferation, differentiation and migration of T and B lympho-
cytes, mast cells and eosinophils [18–20]. Indeed, genetic ablation
of p110d or p110c PI3K in mice has been shown to dampen Th2
immune responses, eosinophilic lung infiltration, and airway
hyperresponsiveness and remodeling [21–23]. Therapeutic strat-
egies targeted at the PI3K/Akt signaling pathway such as using
adenovirus-carrying phosphatase and tensin homologue deleted
on chromosome ten (PTEN) cDNA [40], dominant-negative class
IA PI3K-TAT fusion protein [41], and PI3K non-selective and
isoform-selective small molecule inhibitors [42,43,44] have
demonstrated beneficial effects in experimental asthma models.
Our findings reveal for the first time significant inhibition of
Akt(ser
473) phosphorylation and of its downstream kinases by
artesunate in both OVA-challenged lungs in vivo and EGF-
stimulated normal human bronchial epithelial cells in vitro. Taken
together, we have established that anti-malarial drug artesunate, a
semi-synthetic derivative of artemisinin isolated from the herb
Artemisia annua, can effectively suppress various aspects of OVA-
induced Th2-mediated allergic airway inflammation in mice via
inhibition of the PI3K/Akt signaling pathway.
Figure 4. Effects of artesunate on OVA-induced AHR. Airway
responsiveness of mechanically ventilated mice in response to
aerosolized methacholine was measured 24 hours after the last saline
aerosol or OVA aerosol with pretreatment of either DMSO or 30 mg/kg
artesunate. AHR is expressed as percentage change from the baseline
level of (A) lung resistance (Rl, n=6 mice) and (B) dynamic compliance
(Cdyn, n=6 mice). Rl is defined as the pressure driving respiration
divided by flow. Cdyn refers to the distensibility of the lung and is
defined as the change in volume of the lung produced by a change in
pressure across the lung. *Significant difference from DMSO control,
p,0.05.
doi:10.1371/journal.pone.0020932.g004
Figure 5. Effects of artesunate on OVA-induced inflammatory
gene expression, PI3K/Akt activation and NF-kB DNA-binding
activity in allergic airway inflammation. (A) Lung tissues were
collected 24 hours after the last OVA aerosol challenge. Total mRNA
was extracted using TriZol reagent and the quantitative real time PCR
was performed. All reactions were run in triplicate and three
independent experiments for each target. The relative quantity of
target gene expression was automatically normalized by GADPH as an
internal control and values shown were the ratios of various treatments
to saline group. (B) Immunoblotting of Akt, tuberin, p70S6K and 4E-BP1
in protein extracts of lung tissues isolated from mice 24 hours after the
last saline aerosol or OVA aerosol challenge pretreated with either
DMSO or 30 mg/kg artesunate. b-actin was used as an internal control.
The experiments were repeated for three times (n=3 mice) with similar
pattern of results. (C) Nuclear p65 DNA-binding activity was determined
using a TransAM
TM p65 transcription factor ELISA kit. Values shown are
the mean 6 SEM of four separate experiments. *Significant difference
from DMSO control, p,0.05.
doi:10.1371/journal.pone.0020932.g005
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allergic airway inflammation [1,2]. IL-4, IL-5 and IL-13 can be
produced by various lung resident cells such as bronchial epithelial
cells, mast cells and alveolar macrophages as well as infiltrated
inflammatory cells such as lymphocytes and eosinophils. Our
present results show that artesunate significantly reduced the level
of IL-4, IL-5, IL-13 and eotaxin in BAL fluids from OVA-
challenged mice. They are in line with studies using mice deficient
in p110d or p110c PI3K showing a major drop in Th2 cytokines
and chemokines upon allergen sensitization and challenge [21,22].
Artesunate was found to suppress OVA-induced phosphorylation
of Akt and its downstream signaling molecules tuberin, p70S6K
and 4EBP1, and transactivation of NF-kB in lung samples.
Cumulative evidence has shown that inhibitors targeting at the
p70S6K and NF-kB could dampen Th2 immune responses in
animal models of asthma [45,46]. Therefore, the observed
reduction of IL-4, IL-5, IL-13 and eotaxin levels in BAL fluid
from artesunate-treated mice may be due to inhibition of PI3K/
Akt and its downstream kinases in the inflammatory and airway
resident cells. Furthermore, our in vitro study using direct OVA
stimulation of lymph node cells isolated from artesunate-treated
mice produced markedly lower level of IL-4, IL-5 and IL-13
together with higher IFN-c level as compared with DMSO-treated
mice. These data show that the anti-inflammatory effect of
artesunate is at least in part mediated through a direct suppressive
action on T lymphocytes.
Eosinophils play a central role in the pathogenesis of allergic
inflammation [5,7]. Our present findings showed that artesunate
prevented OVA-induced inflammatory cell infiltration into the
airways as shown by a significant drop in total cell counts and
eosinophil and lymphocyte counts in BAL fluid, and in tissue
eosinophilia in lung sections. To validate the anti-inflammatory
effects of artesunate in a more clinically relevant asthma model, we
also observed a major reduction of total cell and eosinophil counts
in BAL fluid collected from house dust mite extract-challenged-
mice. Leukocyte transmigration into the airways is orchestrated
by cytokines like IL-4, IL-5 and IL-13, and coordinated by specific
chemokines like eotaxin and RANTES in combination with
adhesion molecules such as intercellular adhesion molecule-1
Figure 6. Effects of artesunate on EGF stimulation of normal
human bronchial epithelial cells. (A) Epithelial cells were stimulated
with 100 ng/ml EGF in the presence and absence of 10 mM artesunate
for 5, 15 and 30 minutes before total proteins were extracted for
subsequent immunoblotting analysis. b-actin was used as an internal
control. (B) DNA-binding activity of p65 NF-kB in nuclear extracts of
epithelial cells stimulated with EGF for 30 minutes in the presence and
absence of 10 mM artesunate was determined using a TransAM
TM p65
transcription factor ELISA kit. (C) Epithelial cells were stimulated with
100 ng/ml EGF in the presence and absence of 10 mM artesunate for
12 hours before total mRNA was extracted using TriZol reagent. PCR
products were separated in a 2% agarose gel and visualized under UV
light. b-actin was used as an internal control. Representative gels from 4
separate experiments with similar pattern of results. Values shown are
the mean 6 SEM of three separate experiments. *Significant difference
from DMSO control, p,0.05.
doi:10.1371/journal.pone.0020932.g006
Figure 7. Effects of artesunate on house dust mite extracts-
induced pulmonary inflammatory cell recruitment. Inflammatory
cell counts in BAL fluid obtained from mice 72 hours after the last
house dust mitechallenge (n=6 mice) markedly increased as compared
to saline control (n=4 mice). Artesunate (30 mg/kg, n=6 mice)
significantly suppressed house dust mite-induced increases in BAL fluid
total cell and eosinophil counts as compared with vehicle control
(DMSO, n=5). Differential cell counts were performed on a minimum of
500 cells to identify (Eos), macrophage (Mac), neutrophil (NEU), and
lymphocyte (Lym). *Significant difference from DMSO control, p,0.05.
doi:10.1371/journal.pone.0020932.g007
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E-selectin [7,33]. Cytokine receptor activation by IL-4, IL-5 and
IL-13 induces PI3K/Akt signaling cascade [47,48], and IL-4 and
IL-13 are potent inducers of eotaxin and RANTES expression in
human bronchial epithelial cells [49]. PI3Kc plays an imperative
role in mediating eotaxin-induced eosinophil chemotaxis in vitro
[18]. Inhibition of class IA PI3K in eosinophil has been shown to
block IL-5-induced b2-integrin adhesion of human eosinophils to
ICAM-1 [48]. In addition, selective PI3Kd inhibition in mice
suppressed aeroallergen-induced VCAM-1 and ICAM-1 expres-
sion in lungs [43]. We have demonstrated that artesunate strongly
suppressed ICAM-1, VCAM-1 and E-selectin mRNA expression
and eotaxin production in OVA-challenged lungs, and IL-8,
RANTES and MCP-1 mRNA expression in EGF-stimulated
normal human bronchial epithelial cells. Taken together, the
observed reduction in airway eosinophilia by artesunate may be a
result of combined inhibitory effects on IL-4, IL-5, IL-13, eotaxin
and RANTES production, and on adhesion molecule expression,
secondary to inhibition of PI3K/Akt.
We have also demonstrated a dramatic reduction in airway
mucus production in artesunate-treated mice as compared with
DMSO control. Cumulative evidence indicates that IL-4, IL-5, IL-
6, IL-13, IL-17 and IL-33 induce goblet cell hyperplasia and
mucin production in mice [25,28,29,37]. Mice deficient in p110d
or p110c PI3K had impaired mucus production in response to
aeroallergen challenge [21,22]. Muc5ac gene expression is also
dependent on the transcriptional activity of NF-kB [25,50]. We
also observed a substantial drop in Muc5ac mRNA expression by
artesunate in OVA-challenged lungs. As such, the marked
decrease in mucus production in the lungs of artesunate-treated
mice may be attributable to a significant reduction of Th2 cytokine
levels, together with inhibition of NF-kB transactivation in airway
epithelium.
A family of chitinase proteins including AMCase, Ym1, Ym2
and YKL-40 has recently been found to be markedly elevated in
allergic airway inflammation in human and in mouse asthma
models [30,31,32]. AMCase level is increased in a mouse asthma
model and in asthmatic subjects. When given intratracheally, IL-
13 elevates Ym1 and Ym2 levels in BAL fluid from mice in vivo
[51]. Besides, YKL-40 serum level correlates positively with
asthma severity, airway remodeling and deterioration of pulmo-
nary function in asthmatic subjects [32]. Overall, chitinases may
play a role in airway inflammation and remodeling. Our data
show that artesunate markedly down-regulated AMCase, Ym2
and YKL-40 mRNA expression in the lungs of OVA-challenged
mice. These may be a consequence of the major drop in IL-4 and
IL-13 levels in the airways with artesunate treatment and may
contribute to the diminished pulmonary eosinophilia.
Patients with bronchial asthma produce higher level of exhaled
NO as compared with healthy controls, and the NO level may
reflect the severity of asthma [52]. It appears that increased
exhaled NO is associated with increased iNOS expression in the
lung epithelium of asthma patients [53]. IL-13 has been shown to
induce iNOS expression in normal human bronchial epithelial
cells leading to elevate NO production [26]. PI3K plays an
important role in the dimerization of iNOS for the NO production
[54]. In addition, iNOS gene expression is regulated by the NF-
kBtranscriptional activity [50]. Our results show that artesunate
markedly suppressed the OVA-induced iNOS expression in the
lungs, which may be due to inhibition of PI3K/Akt pathway and
of the downstream NF-kB activity, and the reduced level of IL-13
in the allergic airways.
Activation of PI3K/Akt and its downstream molecules tuberin,
p70S6K and 4E-BP1 lead to airway smooth muscle hypertrophy
and hyperplasia [55,56]. More recently, p110d PI3K has been
shown to mediate IL-13-induced mouse tracheal smooth muscle
hyperreactivity to methacholine [57]. We report here that
artesunate significantly inhibited OVA-induced AHR to increas-
ing concentrations of methacholine. Thus, the observed reduction
of AHR by artesunate may be associated with the reduction in
Th2 cytokine production, tissue eosinophilia, and airway smooth
muscle contractile machinery via inhibition of PI3K/Akt signaling
pathway.
We report here for the first time that the anti-malarial agent
artesunate effectively reduced OVA-induced inflammatory cell
recruitment into BAL fluid, IL-4, IL-5, IL-13 and eotaxin
production, pulmonary eosinophilia, mucus hypersecretion and
AHR in a mouse asthma model potentially via inhibition of the
PI3K/Akt signaling pathway. Artesunate is a clinically effective
drug for both uncomplicated and severe malaria [9,10,11]. Our
present findings support a novel therapeutic use of artesunate in
the treatment of asthma.
Materials and Methods
Animalsand ethics statement
All animal experiments were performed according to the
Institutional guidelines for Animal Care and Use Committee of
the National University of Singapore. Female BALB/c mice, 6
to 8 weeks old (Interfauna, East Yorkshire, UK), were
sensitized and challenged with OVA as described [58]. Briefly,
mice were sensitized by i.p. injections of 20 mgO V Aa n d4m g
Al(OH)3 suspended in 0.1 ml saline on days 0 and 14. On days
22, 23 and 24, mice were challenged with 1% OVA aerosol for
30 minutes. Artesunate (3, 10, and 30 mg/kg; Sigma, St.
Louis, MO) or vehicle (DMSO) in 0.1 ml saline was given by
i.p. injections 1 hour before each OVA aerosol challenge.
Saline aerosol was used as a negative control. For the
development of house dust mite mouse asthma model, female
BALB/c mice were anaesthetized using isoflurane (Halocarbon
Products Corporation, River Edge, NJ, USA) and then
administered through intratracheal route with either 40 mlo f
Dermatophagoidespteronyssinus extracts (100 mg, Greer Laborato-
ries, Lenoir, NC, USA) or saline as a negative control on days
0, 7 and 14 as described [38,39]. Artesunate (30 mg/kg) or
vehicle in 0.1 ml saline was given by i.p on days 6, 7 and 8, and
days 13, 14 and 15. Mice were sacrificedon day 17 and BAL
fluid was collected for total and differential cell countsas
described below.
BAL fluid and serum analysis
Mice were anesthetized 24 hours after the last aerosol challenge
and BAL was performed as described [58]. Briefly, tracheotomy
was performed, and a cannula was inserted into the trachea. Ice-
cold PBS (0.5 ml63) was instilled into the lungs, and BAL fluid
was collected. BAL fluid total and differential cell counts, and
cytokine and chemokine levels were determined as described [58].
IL-4, IL-5 and IL-12 ELISA were obtained from BD PharMingen
(San Diego, CA, USA). Eotaxin, IL-13 and IFN-c ELISA were
purchased from R&D Systems (Minneapolis, MN, USA).
Histologic analysis
Lungs were fixed in 10% neutral formalin, paraffinized, cut into
5-mm sections, and stained with hematoxylin and eosin (H&E) for
examining cell infiltration and with periodic acid-Schiff stain (PAS)
for measuring mucus production. Quantitative analyses of cell
infiltration and mucus production were performed blind as
previously described [56].
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Mice were anesthetized and tracheotomy was performed as
described [58]. The trachea was intubated with a cannula that was
connected to the pneumotach, ventilator and nebulizer. Lung
resistance (Rl) and dynamic compliance (Cdyn) in response to
increasing concentrations of nebulized mechacholine (0.5–
8.0 mg/ml) were recorded using FinePointe
TM data acquisition
and analysis software (Buxco, Wilmington, NC, USA) as described
[58]. Results are expressed as a percentage of the respective basal
values in response to phosphate-buffered saline (PBS).
Cell cultures
To determine the effects of artesunate on OVA-specific immune
responses in lymphocytes, thoracic lymph node cells were
prepared as described [58]. Cells were exposed to 200 mg/ml
OVA for 72 hours. Concanavalin A (Con A, 10 mg/ml) was used
as a positive control. Supernatants from parallel triplicate cultures
were analyzed for cytokine levels by ELISA. Normal human
bronchial epithelial cells (Lonza, Basel, Switzerland) were cultured
in optimized bronchial epithelial bulletkit medium with supple-
ments. Cells of passage numbers 3–6 were pretreated with 10 mM
artesunate or vehicle (0.01% DMSO) 2 hours before stimulation
with 100 ng/ml epidermal growth factor (EGF). Total and nuclear
proteins, and mRNA were extracted from cells at specified time
intervals.
Immunoblotting, mRNA expression and NF-kB DNA-
binding
Lung and cell culture protein lysates (20 mg per lane) were
separated by 10% SDS-PAGE and immunoblots were developed
as described [58]. Immunoblots were probed with anti-Akt, anti-
phospho-Akt (Ser
473), anti-tuberin, anti-phospho-tuberin (Ser
1462),
anti-p70S6K, anti-phospho-p70S6K (Ser
389), anti-4E-BP1, anti-
phospho-4E-BP1 (Ser
65), and anti-b-actin antibodies (Cell Signal-
ing Technology, Beverly, MA). Primers for inflammatory genes
are shown in Table 1 and mRNA expression was analyzed by
quantitative real time PCR (ABI 750 Cycler, Applied Biosystems,
Carlsbad, CA, USA). Nuclear proteins were analyzed for NF-kB
DNA-binding activity using TransAM NF-kB transcription factor
assay kit (Active Motif, Carlsbad, CA).
Statistical analysis
Data are presented as means 6 SEM. One-way ANOVA
followed by Dunnett’s test was used to determine significant
differences between treatment groups. Significant levels were set at
p,0.05.
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